GF Fund Management CO. LTD. Takes Position in Edwards Lifesciences Co. (NYSE:EW)

GF Fund Management CO. LTD. bought a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,583 shares of the medical research company's stock, valued at approximately $1,006,000.

Other hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC raised its position in Edwards Lifesciences by 0.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 43,095 shares of the medical research company's stock valued at $3,190,000 after purchasing an additional 302 shares during the period. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $266,000. CX Institutional purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $294,000. Linden Thomas Advisory Services LLC raised its holdings in shares of Edwards Lifesciences by 2.2% in the fourth quarter. Linden Thomas Advisory Services LLC now owns 10,365 shares of the medical research company's stock worth $767,000 after buying an additional 221 shares during the period. Finally, AlphaMark Advisors LLC raised its holdings in shares of Edwards Lifesciences by 1.1% in the fourth quarter. AlphaMark Advisors LLC now owns 17,740 shares of the medical research company's stock worth $1,313,000 after buying an additional 201 shares during the period. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 1.4%

NYSE EW traded up $1.06 during midday trading on Thursday, hitting $77.72. 4,077,349 shares of the company traded hands, compared to its average volume of 5,155,216. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $45.59 billion, a PE ratio of 11.15, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company's 50-day simple moving average is $73.09 and its 200-day simple moving average is $72.25. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter last year, the firm earned $0.66 EPS. The business's revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the transaction, the vice president now directly owns 22,588 shares in the company, valued at $1,569,414.24. The trade was a 1.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $70.78, for a total value of $796,275.00. Following the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,150,791.86. This represents a 27.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 67,692 shares of company stock worth $4,822,074. Insiders own 0.34% of the company's stock.

Wall Street Analyst Weigh In

EW has been the topic of several recent analyst reports. Evercore ISI reduced their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Canaccord Genuity Group increased their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a report on Friday, April 25th. Truist Financial reduced their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Piper Sandler increased their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $80.20.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.